Navigation Links
Zyomyx, Inc. Receives ISO 13485: 2003 Certification
Date:2/28/2013

FREMONT, Calif., Feb. 28, 2013 /PRNewswire/ -- Zyomyx, Inc., developer of the first quantitative disposable CD4 diagnostic, has achieved ISO 13485: 2003 certification for its quality management system. Certification was awarded by BSI, one of the world's leading certification bodies.

Achieving ISO 13485: 2003 certification is a critical first step toward both WHO Pre-Qualification and a CE mark. WHO Pre-Qualification requires a quality management system to ensure Good Manufacturing Practices (GMP) and is the regulatory clearance recognized by many policy makers, global health funding organizations, and governments of developing countries. A CE mark is the regulatory clearance requirement recognized in Europe and by many other countries and global health funding organizations. 

"ISO 13485 certification is a major corporate milestone for Zyomyx that moves us closer to the expected launch of our innovative CD4 point-of-care test this year," said Peter Wagner , CEO of Zyomyx, Inc. "This strengthens the confidence our customers and partners have in Zyomyx and provides a solid foundation as we adapt our novel platform technology for other clinical applications as a leader in the commercialization of highly accessible cell count diagnostics."

About ISO 13485: 2003

ISO 13485: 2003 is an international standard, globally recognized for establishing quality management systems that consistently meet customer and regulatory requirements for safe and effective medical devices. ISO 13485 is based on quality management principles that have been proven to enhance organization performance. These principles relate to customer focus, management, internal processes and external relationships.

About Zyomyx, Inc.

Zyomyx, Inc., a privately held diagnostics company based in Fremont, California, is an innovator in the development and commercialization of proprietary diagnostic platforms. The Zyomyx product development infrastructure and suite of proprietary assay and surface technologies are ideally suited for the development of affordable, disposable point-of-care diagnostic products, designed to increase access to testing. Zyomyx's immediate focus is an advanced but simple and inexpensive CD4 T-cell point-of-care test that will be launched globally and is configured to meet the needs of developing countries.

For more information, visit http://www.zyomyx.com

Contact: Joanna Sickler , 510-265-8000, jsickler@zyomyx.com


'/>"/>
SOURCE Zyomyx, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. UCSB professor receives award for graphene electronics research
2. Watsons Generic Yaz(R) Receives FDA Approval
3. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
4. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
5. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
6. Intimate Bridge 2 Conception, Inc. Receives $4.3M
7. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
8. BioNeutral Group Receives $400,000 in Equity Financing
9. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
10. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
11. Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... January 12, 2017 , ... ... Vertebral Technologies, Inc., announces the successful outcome of the first lumbar fusion ... VTI (Vertebral Technologies, Inc.) has partnered with Mexico-based medical product company BioMedical ...
(Date:1/12/2017)... AURORA, Colo (PRWEB) , ... January 12, 2017 ... ... and then to targeted treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a ... eLife describes a new drug combination that has stabilized Rosendahl’s disease and increased ...
(Date:1/12/2017)... The report "Direct-Fed Microbials Market by Type (Lactic Acid Bacteria and Bacillus), Livestock (Pork/Swine, Poultry, ... to 2022", published by MarketsandMarkets, the global market is estimated to be valued ... by 2022, at a CAGR of 6.96% from 2016. ... ... ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... clinics in Peru studying the pathogens that cause malaria and tuberculosis. Seeing firsthand ... path of discovery. , Now, as an assistant professor of biology and biotechnology ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/15/2016)... Advancements in biometrics will radically ... wellbeing (HWW), and security of vehicles by ... vehicles begin to feature fingerprint recognition, iris ... monitoring, brain wave monitoring, stress detection, fatigue ... detection. These will be driven by built-in, ...
(Date:12/15/2016)... Dec. 14, 2016 "Increase in mobile transactions ... The mobile biometrics market is expected to grow from ... by 2022, at a CAGR of 29.3% between 2016 ... as the growing demand for smart devices, government initiatives, ... "Software component is expected to grow at a ...
Breaking Biology News(10 mins):